Bexxar (Tositumomab)

Bexxar (Tositumomab) is a targeted radioimmunotherapy used to treat certain types of non-Hodgkin lymphoma, a cancer of the lymphatic system. It combines an antibody (Tositumomab) that specifically attaches to cancer cells with a radioactive substance that delivers a powerful dose of radiation directly to those cells. This targeted approach helps destroy cancer while minimizing damage to healthy tissue. Bexxar is typically used when other treatments haven't been effective, and its goal is to reduce or eliminate cancer cells through precise radiation delivery.